CanSino Biologics (SEHK:6185) - Stock Price, News & Analysis

6185 Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China.

6185 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 92.3% below our estimate of its fair value

Earnings are forecast to grow 117.56% per year

Risk Analysis

No risks detected for 6185 from our risk checks.

CanSino Biologics Inc. Competitors

Shanghai Junshi Biosciences

SEHK:1877

HK$23.4b

AIM Vaccine

SEHK:6660

HK$4.8b

InnoCare Pharma

SEHK:9969

HK$11.6b

Shandong Boan Biotechnology

SEHK:6955

HK$4.9b

Price History & Performance

Summary of all time highs, changes and price drops for CanSino Biologics
Historical stock prices
Current Share Price	HK$20.00
52 Week High	HK$29.15
52 Week Low	HK$14.80
Beta	0.52
11 Month Change	1.83%
3 Month Change	-8.88%
1 Year Change	-15.61%
33 Year Change	-92.37%
5 Year Change	-42.53%
Change since IPO	-42.36%

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

Shareholder Returns

	6185	HK Biotechs	HK Market
7D	7.6%	2.4%	-3.0%
1Y	-15.6%	-20.4%	-3.5%

Return vs Industry: 6185 exceeded the Hong Kong Biotechs industry which returned -20.6% over the past year.

Return vs Market: 6185 underperformed the Hong Kong Market which returned -3.3% over the past year.

Price Volatility

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement	6.4%
Biotechs Industry Average Movement	6.9%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.2%
10% least volatile stocks in HK Market	3.4%

Stable Share Price: 6185 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6185's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	1,494	Xuefeng Yu	www.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
6185 fundamental statistics
Market cap	HK$7.74b
Earnings (TTM)	-HK$949.57m
Revenue (TTM)	HK$695.31m

7.1x

P/S Ratio

-5.2x

P/E Ratio

Is 6185 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6185 income statement (TTM)
Revenue	CN¥634.61m
Cost of Revenue	CN¥471.96m
Gross Profit	CN¥162.65m
Other Expenses	CN¥1.03b
Earnings	-CN¥866.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.51
Gross Margin	25.63%
Net Profit Margin	-136.57%
Debt/Equity Ratio	33.2%

How did 6185 perform over the long term?

See historical performance and comparison

6185 Stock Overview

Rewards

Risk Analysis

CanSino Biologics Inc. Competitors

SEHK:1877

HK$23.4b

SEHK:6660

HK$4.8b

SEHK:9969

HK$11.6b

SEHK:6955

HK$4.9b

Price History & Performance

Recent News & Updates

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Recent updates

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%